Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China
An erratum to this article was published (J Clin Endocrinol Metab, 21 Dec 2023 ↗)
Authors' conclusion
Decreased serum complement 3 and IGF-1 levels and normal/decreased TG levels act as striking biochemical features of TBIRS. High-dose glucocorticoid pulse therapy followed by conventional-dose long-term therapy combined with immunosuppressants achieves good clinical efficacy.
Study context
- Population
- Patients with type B insulin resistance syndrome (TBIRS), Peking Union Medical College Hospital; mean age 49.5 ± 16.5 years3 men · 5 women
- Participants
- 8 patients
- Exposure
- High-dose glucocorticoid pulse then conventional-dose vs conventional glucocorticoid therapy, each with immunosuppressants
- Pulse therapyn = 5
- Conventionaln = 3reference
- Outcome
- Partial remission
- Follow-up
- Within 2 to 4 weeks
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Pulse therapy
5
events
Conventional
2
events
Observational data: associations, not effects.
Further findings
Clinical and biochemical features
- Hyperglycemia with normal/lower TG and lower IGF-1
- 7 patients
- Intractable hypoglycemia
- 1 patient
- Systemic lupus erythematosus
- 5 patients
- Mixed connective tissue disease
- 2 patients
- Undifferentiated connective tissue disease
- 1 patient
- Acanthosis nigricans
- 5 patients
- Hyperandrogenism (women of child-bearing age)
- 3 patients
Remission at follow-up (6 patients tracked) · 10 weeks to 4 years
- Complete remission
- 4
- Partial remission
- 2
Original publication
Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China. J Clin Endocrinol Metab. Published 3 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →